Background: CD276 is a single-pass type I membrane protein that modulates T-cell-mediated immune responses and the development of acute and chronic transplant rejection. It plays a positive regulatory role in bone formation and has a dual role in the bone-immune interface (1). CD276 has been shown to impair type 1 T-helper cell responses and inhibit cytokine production (2). Furthermore, it induces antitumor immunity as it activates both acquired and innate immunity leading to natural killer cell and CD8 T-cell dependent killing of tumor cells (1).

Specificity: Human CD276 recombinant protein and CD276 over-expressing CHO cells were used as an immunogen. This antibody was developed as part of a collaboration between Epitomics, the National Cancer Institute's Center for Cancer Research and the lab of Brad St. Croix. View antibodies from NCI Center for Cancer Research Collaboration

Storage Condition and Buffer: Store at -20 °C. Buffer: Antibody buffer, sodium azide, glycerol, and BSA. Stable for 12 months from date of receipt.

Recommended Dilutions:
WB: 1:1,000 - 10,000
IP: 1:10 - 100
FC: 1:10 - 100

Background References:
1. The UniProt Consortium Ongoing and future developments at the Universal Protein Resource Nucleic Acids Res. 39: D214-D219 (2011).
2. Yamato I et al. Br J Cancer. 2009 Nov 17;101(10):1709-16. Epub 2009 Oct 20.

*Species cross-reactivity is based on WB analysis.